Formulation Development and Evaluation of Fast Disintegrating Tablets of Salbutamol Sulphate, Cetirizine Hydrochloride in Combined Pharmaceutical Dosage Form: A New Era in Novel Drug Delivery for Pediatrics and Geriatrics

Table 9

Stability data of Salbutamol Sulphate, Cetirizine Hydrochloride FDT at temperature (40° ± 2°C) and at ambient humidity.

Evaluation parameters	Time interval
	Data of three primary batches on
	0 day			15th day			30th day
	B-1	B-2	B-3	B-1	B-2	B-3	B-1	B-2	B-3
Hardness (Kg/cm^2) ± S.D	1.5 ± 0.29	1.8 ± 0.29	1.5 ± 0.29	2.5 ± 0.00	2.2 ± 0.29	2.5 ± 0.00	2.5 ± 0.00	2.5 ± 0.29	3.2 ± 0.29
Friability (%)	1	0.6	1	0.1	0.2	0.9	0.6	0.5	0.1
Drug content uniformity (mg) ± S.D	SAL-100.8 ± 3.36,; CET-104.7 ± 1.97	SAL-95.6 ± 2.34,; CET-95.4 ± 2.86	SAL-93.8 ± 1.24,; CET-97.7 ± 3.97	SAL-98.5 ± 2.14,; CET-100 ± 1.78	SAL-99.4 ± 2.67,; CET-96.3 ± 2.07	SAL-90.42 ± 3.64,; CET-95.7 ± 2.78	SAL-92.8 ± 1.98,; CET-95.5 ± 1.97	SAL-99 ± 1.65,; CET-98.1 ± 1.97	SAL-97.6 ± 3.63,; CET-94.2 ± 1.63
Disintegration time (sec) ± S.D	39 ± 2.28	47 ± 1.80	42 ± 3.01	49 ± 2.38	55 ± 3.08	51 ± 1.76	55 ± 2.09	61 ± 1.89	58 ± 2.96

Average of three determinations/batches.
Average of six determinations/batches.